Selected article for: "allergen challenge and subsequent challenge"
Author: Leaker, Brian R.; Singh, Dave; Lindgren, Sam; Almqvist, Gun; Eriksson, Leif; Young, Barbara; O’Connor, Brian
Title: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study
  • Document date: 2019_12_19
    • ID: 15e043uf_47
    Snippet: Preclinical studies in murine models [35, 36] demonstrated that intranasal administration of AZD8848 can confer sustained protection against allergen challenge. The allergen challenge model in man is an important predictor of subsequent efficacy in the treatment of asthma [37] . Inhaled steroids have been shown to inhibit the LAR (AUC 3-10 ) by 50-80% after a single dose, but multiple doses over several weeks are required to demonstrate inhibitio.....
    Document: Preclinical studies in murine models [35, 36] demonstrated that intranasal administration of AZD8848 can confer sustained protection against allergen challenge. The allergen challenge model in man is an important predictor of subsequent efficacy in the treatment of asthma [37] . Inhaled steroids have been shown to inhibit the LAR (AUC 3-10 ) by 50-80% after a single dose, but multiple doses over several weeks are required to demonstrate inhibition of both EAR and LAR [38] . Gauvreau et al. reported a lack of effect on allergen challenge of a novel immunomodulatory agent which induced IFN gamma via TLR9 receptor stimulation [39] . However, this mechanism has a restricted range of stimulatory effects on immune cells in man and is in contrast with AZD8848 which is a TLR7 agonist.

    Search related documents:
    Co phrase search for related documents
    • allergen challenge and challenge model: 1
    • allergen challenge and effect lack: 1
    • allergen challenge and IFN gamma: 1, 2
    • allergen challenge and intranasal administration: 1
    • allergen challenge and murine model: 1
    • allergen challenge and Preclinical study: 1
    • allergen challenge and single dose: 1
    • asthma treatment and IFN gamma: 1
    • asthma treatment and intranasal administration: 1, 2, 3
    • asthma treatment and multiple dose: 1
    • asthma treatment and murine model: 1, 2
    • asthma treatment and Preclinical study: 1, 2
    • asthma treatment and single dose: 1
    • challenge model and IFN gamma: 1, 2
    • challenge model and immune cell: 1, 2, 3, 4, 5, 6
    • challenge model and intranasal administration: 1, 2, 3, 4, 5, 6
    • challenge model and multiple dose: 1
    • challenge model and murine model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • challenge model and single dose: 1, 2, 3, 4, 5, 6, 7, 8, 9